Sodium Glucose Co-Transporter 2 Inhibition Following Acute Myocardial Infarction: The DAPA-MI and EMPACT-MI Trials

JACC Heart Fail. 2024 May;12(5):949-953. doi: 10.1016/j.jchf.2024.01.019. Epub 2024 Apr 6.

Authors

Alexander Peikert¹, Muthiah Vaduganathan²

Affiliations

¹ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; University Heart Center Graz, Department of Cardiology, Medical University of Graz, Graz, Austria.
² Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: mvaduganathan@bwh.harvard.edu.

PMID: 38583168
DOI: 10.1016/j.jchf.2024.01.019

No abstract available

Keywords: SGLT2 inhibitors; acute myocardial infarction; clinical trials; heart failure.

Publication types

Letter
Research Support, Non-U.S. Gov't
Editorial

MeSH terms

Benzhydryl Compounds* / therapeutic use
Glucosides / therapeutic use
Humans
Myocardial Infarction* / drug therapy
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Benzhydryl Compounds
empagliflozin
dapagliflozin
Glucosides